Rubraca® (rucaparib) – Indication update
December 21, 2022 - The FDA approved an update to the Rubraca (rucaparib) drug label, restricting the maintenance treatment of recurrent ovarian cancer indication to only the patient population with a deleterious BRCA mutation (germline and/or somatic).
Download PDF
